Reaction products of diazotised Sodium hydrogen 4-amino-5-hydroxynaphthalene-2,7-disulphonate coupled with Resorcinol (1:1), coupled with diazotised 5-amino-2-anilinobenzenesulphonic acid (1:2), coupled with diazotised 4-nitroaniline (1:1), sodium salts

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

other: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

13 April to 23 May, 2017

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Remarks:

study conducted on the analogue substance; the read across justification is detailed in section 13. The Reliability of the Source Study is 1.

Justification for type of information:

The complete read across justification is detailed in section 13.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2017

Report date:

2017

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Version / remarks:

2001

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Version / remarks:

2008

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1100 (Acute Oral Toxicity)

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Acid Brown 107 - Similar Substance 01

IUPAC Name:

Acid Brown 107 - Similar Substance 01

Test material form:

solid: particulate/powder

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
-Source: Envigo RMS s.r.l., San Pietro al Natisone (UD), Italy
-Females nulliparous and non-pregnant: yes
-Age at study initiation: 7 weeks old (first batch); 6-7 weeks old (second batch)
-Weight at study initiation: 158-161 grams (first batch); 168.3-189.3 grams (second batch)
-Fasting period before study: food was removed from the cages overnight prior to dosing (Day -1) and was made available approximately 4 hours after dosing.
-Housing: 3 animals per cage during the study; up to 5 animals during acclimatisation in Polisulphone solid bottomed cages measuring 59.5×38×20 cm with nesting material provided into suitable bedding bags
-Diet: 4 RF 18; ad libitum
-Water: drinking water supplied to each cage via a water bottle; ad libitum
-Acclimation period: at least 5 days
-Veterinary health check: during acclimatisation period

ENVIRONMENTAL CONDITIONS
-Temperature: 22 °C ± 2 °C
-Humidity: 55 % ± 15 %
-Air changes: Approximately 15 to 20 air changes per hour
-Photoperiod: 12 hours cycle dark/light with artificial fluorescent tube.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Remarks:

Softened

Details on oral exposure:

- Dosing method: the formulated test item was administered at a dose volume of 10mL/kg using a plastic feeding tube attached to a graded syringe.

Doses:

Group 1: 300 mg/kg bw
Group 2: 300 mg/kg bw
Group 3: 2000 mg/kg bw
Group 4: 2000 mg/kg bw

No. of animals per sex per dose:

Three females per group; two groups per dose.

Control animals:

no

Details on study design:

Frequency of treatment: once only on Day 1
- Duration of observation period following administration: 14 days
- Mortality and morbidity: throughout the study, all animals were checked twice daily
-Frequency of observations:
Animals were observed for clinical signs as indicated below:
-Day of dosing
Session 1: on dosing
Session 2: approximately 0.5 hour after dosing
Session 3: approximately 2 hours after dosing
Session 4: approximately 4 hours after dosing
-Daily thereafter for a total of 14 days (Session 1).
-Frequency of weighing: all animals were weighed at allocation to the study (Day -1), on the day of dosing (Day 1) and on Days 2, 8 and 15.
-Necropsy of survivors performed: yes

Results and discussion

Effect levels

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

In the first group dosed at 300 mg /kg, one animal was found dead on Day 2 of the observation period.
In the second group dosed at the same dose level, no death occurred.
Both in the third and in the fourth groups (dosed at 2000 mg/kg), no death occurred.

Clinical signs:

In both groups dosed at 300 mg /kg, no clinical signs were observed.
In the third group dosed at 2000 mg/kg, no clinical signs were observed.
In the fourth group at the same dose level, only black staining on the tail of animals was observed for the entire observation period.

Body weight:

Changes in body weight observed during the study were within the expected range for this strain and age of animals.

Gross pathology:

Abnormalities observed during the necropsy of the early decedent animal consisted in abnormal colour (dark red) of lungs, brain, thymus, heart and thoracic cavity. In addition, abnormal content (dark fluid) in the thoracic cavity was recorded. No abnormalities were observed at necropsy examination performed at the end of the observation period on the surviving animals treated at 300 mg/kg and in animals treated at 2000 mg/kg. Only two animals (Step 4) showed dark staining on the tail.

Applicant's summary and conclusion

Interpretation of results:

other: not classified according to the CLP Regulation (EC) no. 1272/2008

Conclusions:

The acute toxicity estimate (ATE) was found to be greater than 2000 mg/kg body weight.

Executive summary:

The acute toxicity of the test item was investigated following a single oral administration to Sprague Dawley rats, followed by a 14-day observation period, according to the OECD Guideline 423 (2001) and the EU Method B.1 Tris "Acute Oral Toxicity - Acute Toxic Class Method" (2008). Two groups, each containing 3 females, were initially dosed at 300 mg/kg bw; a third group of 3 females was dosed at 2000 mg/kg bw. Finally, a fourth group of 3 females was also administered 2000 mg/kg bw. Animals were monitored for clinical signs, mortality and body weight change. At the end of the observation period, all animals were sacrificed and subjected to necropsy.

No mortality occurred at any dose levels except for one animal from group 1 which was found dead on Day 2 of the observation period. No clinical signs were observed at any dose levels except for black staining on the tail of all 3 animals of the fourth group dosed at 2000 mg/kg bw which was observed over the entire observation period. Body weight changes recorded during the study were within the expected range for this strain and age of animals. No abnormalities were observed in animals of any group at necropsy. Only two animals in the fourth group dosed at 2000 mg/kg showed dark staining on the tail. The animal which died on day 2 (group 1) presented abnormal colouration (dark red) of the lungs, brain, thymus, heart and thoracic cavity; in addition, abnormal content (dark fluid) in the thoracic cavity was recorded.

These results indicate that the test item did not induce toxic effects in the rat following a single oral administration of 2000 mg/kg bw. Based on mortality, the acute toxicity estimate (ATE) was found to be greater than 2000 mg/kg bw.